Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Connect Biopharma Holdings (CNTB) EBITDA (2024 - 2025)

Connect Biopharma Holdings' EBITDA history spans 2 years, with the latest figure at -$17.1 million for Q3 2025.

  • For Q3 2025, EBITDA fell 38.97% year-over-year to -$17.1 million; the TTM value through Sep 2025 reached -$50.0 million, changed N/A, while the annual FY2024 figure was -$16.3 million, 76.42% up from the prior year.
  • EBITDA for Q3 2025 was -$17.1 million at Connect Biopharma Holdings, down from -$12.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $14.9 million in Q2 2024 and bottomed at -$17.1 million in Q3 2025.